OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor. 


Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Advances in Lung Transplant

Submission Deadline: May 30, 2023 (Open) Submit Now

Guest Editor

Shambhu Aryal, MD,FCCP

Inova Advanced Lung Disease an Lung Transplant Program, Inova Fairfax Medical Campus, 3300 Gallows Road, Falls Church, VA 22042, USA

Website | E-Mail

Research Interests: Lung Transplantation; Interstitial Lung Disease; Sarcoidosis; Pulmonary Hypertension; Cystic Fibrosis

About This Topic

OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation. This is seeking original manuscripts for a Special Issue on: “Advances in Lung Transplant” scheduled to appear in the first half of 2023.
Lung transplantation is an established life-saving treatment for select patients who have failed conventional conservative medical therapy for their lung disease. After the first successful surgery in the early 1980s, the number of lung transplantations performed worldwide has increased steadily to about 5000 transplants per year. This increase in numbers has enriched the experience of the lung transplant community and led to several advances in the field. Improvement in surgical techniques and peri-operative management in the first couple of decades of lung transplantation led to improvement in early post-transplant survival. More recently, a lot of interest and resources are being put into important areas including primary graft dysfunction, organ preservation and rehabilitation, biomarkers in lung transplantation, antibody mediated rejection, and chronic lung allograft dysfunction. These works are expected to significantly improve both short-term and long-term outcomes including survival and quality of life for lung transplant recipient.

The special issue will provide a forum for presenting current research works and clinical results showing advancement in the field of lung transplantation noted above. The special issue will also be open to any author. Each submission will be reviewed by at least two reviewers to ensure a very high quality of papers selected for the Special Issue.


Lung transplantation; Acute cellular rejection; Antibody mediated rejection; Primary graft dysfunction; Donor derived cell-free DNA; Biomarkers for lung transplantation; Chronic lung allograft dysfunction; Bronchiolitis obliterans syndrome; Restrictive allograft syndrome; Extracorporeal photopheresis


Open Access Original Research

Lung Transplantation for COVID-19 Related Lung Disease: A Follow-Up Study of Outcomes from a Medium-Size Lung Transplant Programd

Received: 01 May 2023;  Published: 17 July 2023;  doi: 10.21926/obm.transplant.2303193


In the United States of America, COVID-19 acute respiratory distress syndrome (ARDS) and post-COVID pulmonary fibrosis (PCPF) are raising indications for lung transplant (LT). Another indication for LT is underlying fibrosis with SARS-CoV-2 induced interstitial lung disease exacerbation or rapid progressing fibrosis. Only a few centers have [...]
Open Access Review

Biomarkers in the Management of the Lung Transplant Allograft: A Focus on Donor-derived Cell-free DNA

Received: 16 March 2023;  Published: 26 June 2023;  doi: 10.21926/obm.transplant.2302190


Advances in the use of molecular biomarkers to guide management of lung transplant recipients are emerging. One such biomarker, donor-derived cell-free DNA (dd-cfDNA), has the potential to alter traditional approaches of lung transplant management, including the detection of acute rejection or infection, surveillance monitoring [...]
Open Access Review

A Breath of Fresh Air - Lung Transplantation Has Come of Age

Received: 11 January 2023;  Published: 04 April 2023;  doi: 10.21926/obm.transplant.2302179


A boundless spectrum of chronic lung diseases is said to effect over 500 million persons globally. Lung transplantation is a well-established therapeutic option for patients suffering from end-stage lung diseases, however waitlist mortality and primary graft failure remain major determinants as post-transplantation 5-year survival is just [...]
Open Access Case Report

Lung Transplantation from A Donor with Previous SARS-CoV-2 Infection: 1-Year Outcomes

Received: 25 October 2022;  Published: 06 January 2023;  doi: 10.21926/obm.transplant.2301173


Few reports have described successful lung transplantation from a donor with a history of SARS-CoV-2 infection, and outcomes beyond 3 to 6 months remain unknown. After weighing the urgency and life-saving benefits of lung transplantation against the risk of viral transmission, we successfully performed a bilateral lung transplant from a donor [...]